Provided by Tiger Fintech (Singapore) Pte. Ltd.

Jasper Therapeutics

5.94
-0.0700-1.16%
Post-market: 6.030.0900+1.52%17:11 EDT
Volume:220.93K
Turnover:1.32M
Market Cap:89.23M
PE:-1.13
High:6.10
Open:6.05
Low:5.86
Close:6.01
Loading ...

Jasper Therapeutics Unveils New Insights on Briquilimab's Efficacy in Mast Cell Mediated Diseases

Reuters
·
21 May

Jasper Therapeutics Is Maintained at Buy by UBS

Dow Jones
·
14 May

RBC Adjusts Price Target on Jasper Therapeutics to $46 From $48, Maintains Outperform Speculative Risk Rating

MT Newswires Live
·
13 May

Jasper Therapeutics Inc : UBS Cuts Target Price to $33 From $38

THOMSON REUTERS
·
13 May

Jasper Therapeutics Faces Financial Challenges Amid Rising R&D Costs

TIPRANKS
·
13 May

Jasper Therapeutics reports Q1 EPS ($1.41), consensus ($1.48)

TIPRANKS
·
13 May

Jasper Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
13 May

Jasper Therapeutics Q1 EPS $(1.41) Misses $(1.33) Estimate

Benzinga
·
13 May

Jasper Therapeutics Q1 Income From Operation USD -21.802 Million

THOMSON REUTERS
·
13 May

Jasper Therapeutics Q1 EPS USD -1.41

THOMSON REUTERS
·
13 May

Jasper Therapeutics Inc expected to post a loss of $1.31 a share - Earnings Preview

Reuters
·
09 May

BRIEF-Jasper Therapeutics Inc Files For Common Stock Offering Of Up To $100 Million - SEC Filing

Reuters
·
27 Mar

Jasper Therapeutics Files $300 Million Mixed Shelf

MT Newswires Live
·
20 Mar

Jasper Therapeutics Signs New Sales Agreement with Jefferies

TIPRANKS
·
20 Mar

BRIEF-Jasper Therapeutics terminates Cantor sales agreement

Reuters
·
20 Mar

Jasper Therapeutics files $300M mixed securities shelf

TIPRANKS
·
20 Mar

Jasper Therapeutics Price Target Maintained With a $40.00/Share by HC Wainwright & Co.

Dow Jones
·
12 Mar

Promising Innovations in Chronic Urticaria Treatment Drive Buy Rating for Jasper Therapeutics

TIPRANKS
·
12 Mar

Jasper Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
03 Mar

Analysts’ Top Healthcare Picks: Coya Therapeutics, Inc. (COYA), Jasper Therapeutics (JSPR)

TIPRANKS
·
03 Mar